Search Results - "Amatu, A"

Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer by Amatu, A, Sartore-Bianchi, A, Bencardino, K, Pizzutilo, E G, Tosi, F, Siena, S

“…The tropomyosin receptor kinase (TRK) family of receptor tyrosine kinases are encoded by NTRK genes and have a role in the development and normal functioning…”
Get full text

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis by Cremolini, C., Di Bartolomeo, M., Amatu, A., Antoniotti, C., Moretto, R., Berenato, R., Perrone, F., Tamborini, E., Aprile, G., Lonardi, S., Sartore-Bianchi, A., Fontanini, G., Milione, M., Lauricella, C., Siena, S., Falcone, A., de Braud, F., Loupakis, F., Pietrantonio, F.

“…While the negative prognostic role of BRAF V600E mutation in metastatic colorectal cancer (mCRC) is well established, the impact of BRAF codons 594 and 596…”
Get full text

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer by Barault, L., Amatu, A., Bleeker, F.E., Moutinho, C., Falcomatà, C., Fiano, V., Cassingena, A., Siravegna, G., Milione, M., Cassoni, P., De Braud, F., Rudà, R., Soffietti, R., Venesio, T., Bardelli, A., Wesseling, P., de Witt Hamer, P., Pietrantonio, F., Siena, S., Esteller, M., Sartore-Bianchi, A., Di Nicolantonio, F.

“…O6-methyl-guanine-methyl-transferase (MGMT) silencing by promoter methylation may identify cancer patients responding to the alkylating agents dacarbazine or…”
Get full text

Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer by Amatu, A., Barault, L., Moutinho, C., Cassingena, A., Bencardino, K., Ghezzi, S., Palmeri, L., Bonazzina, E., Tosi, F., Ricotta, R., Cipani, T., Crivori, P., Gatto, R., Chirico, G., Marrapese, G., Truini, M., Bardelli, A., Esteller, M., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S.

“…Objective response to dacarbazine, the intravenous form of temozolomide (TMZ), in metastatic colorectal cancer (mCRC) is confined to tumors harboring…”
Get full text

Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor by Siravegna, G, Sartore-Bianchi, A, Mussolin, B, Cassingena, A, Amatu, A, Novara, L, Buscarino, M, Corti, G, Crisafulli, G, Bartolini, A, Tosi, F, Erlander, M, Di Nicolantonio, F, Siena, S, Bardelli, A

“…Monitoring response and resistance to kinase inhibitors is essential to precision cancer medicine, and is usually investigated by molecular profiling of a…”
Get full text

Strategies to tackle RAS-mutated metastatic colorectal cancer by Patelli, G., Tosi, F., Amatu, A., Mauri, G., Curaba, A., Patanè, D.A., Pani, A., Scaglione, F., Siena, S., Sartore-Bianchi, A.

“…The RAS oncogene is among the most commonly mutated in cancer. RAS mutations are identified in about half of patients diagnosed with metastatic colorectal…”
Get full text

Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ) by Alsina, M., Varga, A., Amatu, A., Schellens, J.H.M., Witteveen, P.O., Boni, V., Moreno, V., Bol, K., Lourbakos, A., Magin Ferrer, M., Wasserman, E.

Get full text

Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management by Vallerio, P., Orenti, A., Tosi, F., Maistrello, M., Palazzini, M., Cingarlini, S., Colombo, P., Bertuzzi, M., Spina, F., Amatu, A., Lombardo, R., Prata, I., Scaglione, F., Vighi, G.D., Severgnini, B., Siena, S., Giannattasio, C., Boracchi, P., Sartore-Bianchi, A.

“…Vascular endothelial growth factor receptor (VEGFR)-targeted tyrosine kinase inhibitors (TKIs) are widely used in cancer treatment and burdened by…”
Get full text

Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study by Raimondi, A., Di Maio, M., Peverelli, G., Morano, F., Corallo, S., Bergamo, F., Cremolini, C., Smiroldo, V., Amatu, A., Tampellini, M., Fanchini, L., Murialdo, R., Clavarezza, M., Noventa, S., Adamo, V., Ratti, M., Petrelli, F., Antonuzzo, L., Palermo, M., de Braud, F., Di Bartolomeo, M., Pietrantonio, F.

Get full text

OEM-TACE: A New Therapeutic Approach in Unresectable Intrahepatic Cholangiocarcinoma by Poggi, Guido, Amatu, A., Montagna, B., Quaretti, P., Minoia, C., Sottani, C., Villani, L., Tagliaferri, B., Sottotetti, F., Rossi, O., Pozzi, E., Zappoli, F., Riccardi, A., Bernardo, G.

“…Intrahepatic cholangiocarcinoma (ICC) is a rare life-threatening disease, whose only treatment with potential for cure is surgical resection. However, only 27%…”
Get full text

Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study by Raimondi, A., Fucà, G., Leone, A.G., Lonardi, S., Antoniotti, C., Smiroldo, V., Amatu, A., Tampellini, M., Ritorto, G., Murialdo, R., Clavarezza, M., Zaniboni, A., Berenato, R., Ratti, M., Corallo, S., Morano, F., Di Bartolomeo, M., Di Maio, M., Pietrantonio, F.

“…The safety and efficacy outcome of elderly metastatic colorectal cancer (mCRC) patients fit enough to receive combination chemotherapy plus biological agents…”
Get full text

Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO) by Pizzutilo, E.G., Agostara, A.G., Oresti, S., Signorelli, D., Stabile, S., Lauricella, C., Motta, V., Amatu, A., Ruggieri, L., Brambilla, M., Occhipinti, M., Proto, C., Giusti, R., Filetti, M., Genova, C., Barletta, G., Gelsomino, F., Bennati, C., Siringo, M., Di Fazio, G.R., Russano, M., Montrone, M., Gariazzo, E., Roca, E., Bordi, P., Delmonte, A., Scimone, A., Belluomini, L., Mazzoni, F., Carta, A., Pelizzari, G., Viscardi, G., Morgillo, F., Gelibter, A., Gori, S., Berardi, R., Cortinovis, D., Ardizzoni, A., Veronese, S.M., Sartore-Bianchi, A., Giannetta, L.G., Cerea, G., Siena, S.

“…Osimertinib represents the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC) harboring classical epidermal growth factor…”
Get full text

54 MGMT methylation assessed by methyl-BEAMing technique is a prognostic and predictive biomarker in glioblastoma and metastatic colorectal cancer patients by Barault, L, Amatu, A, Bleeker, F.E, Moutinho, C, Cassingena, A, Tosi, F, Venesio, T, Esteller, M, Bardelli, A, Siena, S, Sartore-Bianchi, A, Di Nicolantonio, F

Get full text

2015 Cavitation of lung metastases induced by regorafenib in patients with colorectal carcinoma: Data from the phase III CORRECT study by Ricotta, R, Verrioli, A, Ghezzi, S, Grothey, A, Cremolini, C, Argiles, G, Adenis, A, Ychou, M, Barone, C, Bouchet, O, Humblet, Y, Mineur, L, Sobrero, A, Peeters, M, Van Cutsem, E, Porcu, L, Amatu, A, Sartore-Bianchi, A, Vanzulli, A, Siena, S

Get full text

Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer by Sartore-Bianchi, A, Bencardino, K, Cassingena, A, Venturini, F, Funaioli, C, Cipani, T, Amatu, A, Pietrogiovanna, L, Schiavo, R, Di Nicolantonio, F, Artale, S, Bardelli, A, Siena, S

“…SUMMARY Metastatic colorectal cancer (mCRC) patients carrying KRAS mutated tumors do not benefit from epidermal growth factor receptor (EGFR)-targeted…”
Get full text

Post-traumatic pulmonary and cerebral fat embolism by Imberti, R, Scagnelli, P, Amatu, A

Get full text

P-330 ERBB2 mutations in metastatic colorectal cancer: From clinicopatholgical features to potential treatment implications in a real-world cohort by Vaghi, C., Mauri, G., Amatu, A., Tosi, F., Bonazzina, E., Bencardino, K., Siena, S., Bianchi, A. Sartore

Get full text

5109 Brain metastases (BM) in HER2-overexpressing metastatic breast cancer (MBC): what changed in the trastuzumab therapy era? A monoinstitutional experience by Bernardo, G, Palumbo, R, Bernardo, A, Teragni, C, Poggi, G, Montagna, B, Amatu, A, Sottotetti, F, Tagliaferri, B, Strada, M.R

Get full text

9091 Activity, safety and compliance of sequential chemotherapy with cisplatin (CDDP) plus oral vinorelbine (VNRos) followed by three-weekly docetaxel (DOC) as first-line treatment for advanced non-small cell lung cancer (NSCLC): a single-centre phase II study by Teragni, C, Palumbo, R, Bernardo, A, Strada, M.R, Poggi, G, Amatu, A, Montagna, B, Tagliaferri, B, Sottotetti, F, Bernardo, G

Get full text

5081 Triple combination of 3-weekly trastuzumab (T) plus oral vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-positive metastatic breast cancer (MBC): an active and well-tolerated regimen that allows patient compliance by Palumbo, R, Bernardo, A, Strada, M.R, Poggi, G, Teragni, C, Amatu, A, Frascaroli, M, Montagna, B, Sottotetti, F, Bernardo, G

Get full text